Merck
CN
  • Pediatric super-refractory status epilepticus treated with allopregnanolone.

Pediatric super-refractory status epilepticus treated with allopregnanolone.

Annals of neurology (2014-11-05)
Eileen Broomall, JoAnne E Natale, Michele Grimason, Joshua Goldstein, Craig M Smith, Celia Chang, Stephen Kanes, Michael A Rogawski, Mark S Wainwright
摘要

Super-refractory status epilepticus is a life-threatening condition. Resistance to benzodiazepine and barbiturate treatment for this disorder is thought to be due to internalization of synaptic γ-aminobutyric acid (GABA)A receptors, and withdrawal of benzodiazepines and barbiturates during treatment often triggers seizure recurrence. The neurosteroid allopregnanolone acts as a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors. Here we describe the use of allopregnanolone in 2 pediatric patients with super-refractory status epilepticus. This treatment allowed the general anesthetic infusions to be weaned with resolution of status epilepticus. This is the first report of allopregnanolone use to treat status epilepticus in children.

材料
货号
品牌
产品描述

Supelco
左乙拉西坦, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
苯妥英钠, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
5,5-二苯基海因, ≥98%
USP
苯妥英, United States Pharmacopeia (USP) Reference Standard
苯妥英钠, European Pharmacopoeia (EP) Reference Standard
USP
左乙拉西坦, United States Pharmacopeia (USP) Reference Standard
苯妥英钠, European Pharmacopoeia (EP) Reference Standard
左乙拉西坦, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Felbamate